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Abstract: Polycystic ovary syndrome (PCOS) is a common endocrinopathy that is associated with an
adverse metabolic profile including reduced postprandial thermogenesis. Although abnormalities in
adipose tissue function have been widely reported in women with PCOS, less is known about direct
effects of androgen on white and, particularly, brown adipocytes. The purpose of this study was
to investigate the effect of the nonaromatizable androgen dihydrotestosterone (DHT) on (1) lipid
accumulation and expression of adipogenic markers in immortalized mouse brown adipose cell
lines (IMBATs), (2) mitochondrial respiration in IMBATs, (3) mitochondrial DNA content and gene
expression, (4) expression of brown adipose tissue (BAT) markers and thermogenic activation. In ad-
dition, we profiled the relative levels of 38 adipokines secreted from BAT explants and looked at
androgen effects on adipokine gene expression in both IMBATs and immortalized mouse white adi-
pose (IMWATs) cell lines. Androgen treatment inhibited IMBAT differentiation in a dose-dependent
manner, reduced markers of adipogenesis, and attenuated the β-adrenoceptor-stimulated increase
in uncoupling protein-1 (UCP1) expression. In explants of mouse interscapular BAT, androgen
reduced expression of UCP1, peroxisome proliferator-activated receptor-γ coactivator-1 (PCG-1) and
Cidea. Significantly, as well as affecting genes involved in thermogenesis in BAT, androgen treatment
reduced mitochondrial respiration in IMBATs, as measured by the Seahorse XF method. The results
of this study suggest a role for excess androgen in inhibiting brown adipogenesis, attenuating the
activation of thermogenesis and reducing mitochondrial respiration in BAT. Together, these data
provide a plausible molecular mechanism that may contribute to reduced postprandial thermogenesis
and the tendency to obesity in women with PCOS.
Keywords: PCOS; androgens; brown adipose tissue; mitochondrial respiration; UCP1
1. Introduction
Classically considered little more than a passive reservoir for energy storage, adi-
pose tissue is now recognized as an active endocrine organ, involved in the regulation
of metabolism and whole-body energy homeostasis. Adipocytes secrete a wide range
of hormones and cytokines, collectively known as adipokines, that can modulate sev-
eral physiological systems including regulation of appetite and satiety, insulin sensitivity,
energy expenditure and reproductive function [1–4].
Adipose tissue exists in two main forms: white adipose tissue (WAT) and brown
adipose tissue (BAT), and these differ in both morphology and physiology. WAT stores
large amounts of energy in a unilocular lipid droplet, ready to be released as fatty acids
for any future metabolic needs [5] whereas BAT is distinguished by its unique capacity
to dissipate energy as heat in a process called non-shivering thermogenesis [6]. BAT is
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characterized by multiple small lipid droplets and abundant mitochondria and responds
to cold or adrenergic stimuli by uncoupling oxidative phosphorylation from ATP synthesis
to generate heat via the actions of uncoupling protein 1 (UCP1) [6]. Positron-emission
tomography (PET) has confirmed the existence of functional BAT in the paracervical and
supraclavicular regions of healthy, human adults [7]. Furthermore, it has become increas-
ingly recognized that there is an inverse correlation between the amount of functional BAT
and BMI, suggesting that its energy dissipating function may play a role in the development
of obesity [8].
Adiposity is emerging as an important factor in causing or, at least exacerbating,
common and complex disorders such as type-2 diabetes and polycystic ovary syndrome
(PCOS). PCOS is the most common endocrinopathy in women, affecting between 5% and
10% of females of reproductive age [9]. It is characterized by hyperandrogenemia, is the
principal cause of menstrual irregularity and anovulatory infertility and is associated with
an adverse metabolic profile including obesity and insulin resistance. It is a significant
risk factor for development of type-2 diabetes [10]. The prevalence of overweight or
obesity in women with PCOS is between 40% and 90% and there is a strong association
between adiposity and the severity of the clinical, biochemical and metabolic features
of PCOS [11]. Furthermore, even modest weight loss of 5% of body weight has been
shown to result in significant improvements in both symptoms of hyperandrogenism and
ovulatory function [12].
While a clear link between increased adiposity and the severity of PCOS exists, the rela-
tionship between hyperandrogenemia and adipose tissue is less clear. There is evidence that
increased adiposity directly increases androgen synthesis, partly due to accompanying hyper-
insulinemia but also as a result of an effect of adipokines on ovarian steroidogenesis [10,13].
Comim et al. showed that, using cultured theca cells, the adipokines visfatin and leptin
increased production of androstenedione while, in contrast (but in line with its anti-obesity
effects), adiponectin suppressed production of androstenedione and steroidogenic en-
zymes [13]. Adipocyte dysfunction has been previously reported in women with PCOS
with hyperandrogenism thought to be a driving factor. Increased adipocyte diameter and
depot-specific changes in catecholamine-mediated lipolysis have also been reported in
women with PCOS [14,15]. Differentiation of 3T3-L1 cells into adipocytes is inhibited by
testosterone and androgens inhibit differentiation of human preadipocytes and reduce
lipid metabolism in human adipose tissue explants [16,17]. AR knockout mice, in contrast,
show increased adipogenesis and adipocyte size [18]. Finally, using transcriptomics, recent
studies have looked at the global response to androgens in mice treated with dihydrotestos-
terone (DHT) [19] and demonstrated that, in agreement with previous studies, genes
involved in adipocyte differentiation, adipogenesis and energy expenditure are modulated
by androgen treatment.
The close association of PCOS with obesity and metabolic dysfunction suggests a role
for adipokines as a link between inherent metabolic and reproductive abnormalities. A few
studies have looked at a small number of adipokines in women with and without PCOS.
The overarching trend is for adipokine levels to be raised in serum of women with PCOS
and this is the case for resistin, leptin and visfatin [20]. In contrast, adiponectin levels
are reduced in women with PCOS and this is supported by an in-vitro study by Xu et al.,
revealing that testosterone reduces the secretion of high molecular-weight adiponectin in
visceral adipose tissue [21]. Although abnormal serum levels of adipokines in PCOS have
been reported, little is known about the direct effects of androgens on adipokine expression
in adipose tissue itself [22].
Importantly, there is evidence that androgens have an inhibitory action on BAT func-
tion and that this effect has implications for the development and manifestation of PCOS.
Firstly, there are sex differences in energy expenditure, with female rodents being more
efficient than males in the adaptive production of heat in response to feeding or postpran-
dial thermogenesis [23]. Support for this being an androgen-mediated phenomenon is
provided from a study of neonatally androgenized female mice which have been shown to
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have decreased brown adipose mass and reduced energy expenditure [24]. Mice that over-
express the androgen receptor have less BAT. In a prenatally androgenized sheep model
of PCOS, postprandial thermogenesis is also suppressed [25]. Furthermore, testosterone
has been shown to reduce UCP1 and mitochondrial biogenesis in rat BAT in-vitro and to
inhibit the transcription of PGC1a, a key element in UCP1 expression and mitochondrial
biogenesis [26,27]. The likely relevance of BAT function to PCOS is further illustrated by
studies which indicate that stimulation of BAT activity [28] or transplantation of BAT to
rodent models of PCOS can improve reproductive and metabolic function [22].
In the present study, we evaluated the expression of the androgen receptor (AR)
protein in immortalized, mouse brown adipose cell lines (IMBATs), examining expression
in both preadipocytes and fully differentiated adipocytes. We then investigated the effect
of the nonaromatizable androgen DHT on lipid accumulation and expression of adipogenic
markers in differentiated IMBATs. We examined the effect of androgen exposure on
interscapular BAT explants by measuring gene expression of key BAT markers including
uncoupling protein-1 (UCP1) and peroxisome proliferator-activated receptor-γ coactivator-
1 (PCG-1). To understand BAT function in more detail we profiled the relative levels of
38 adipokines secreted from BAT explants. The effects of DHT on gene expression of a
panel of 25 adipokines in IMBATs were compared with the profile obtained after similar
treatment of IMWATs.
Finally, we investigated the effect of androgen on BAT energy expenditure by pre-
treating brown adipocytes with DHT and then measuring the β-adrenoceptor-stimulated
increase in UCP1. We went on to examine the effect of androgen on mitochondrial respi-
ration in BAT. These studies were designed to improve our understanding of androgen
interactions with BAT function and how this could contribute to a disordered energy
balance in PCOS.
2. Results
2.1. Androgen Receptor Protein Is Expressed in IMBAT Preadipocytes and Adipocytes
Androgen receptor protein was detected by immunohistochemistry in preadipocytes
and differentiated IMBATs. Expression of AR protein, in cells that had not been exposed
to DHT, was located predominantly in the cytoplasm of preadipocytes and in the cy-
toplasm surrounding the lipid droplets in the differentiated adipocyte, as well as the
preadipocytes (Figure 1A).
2.2. DHT Inhibits IMBAT Preadipocyte Differentiation in a Dose-Dependent Manner
To examine the role of androgen signaling in brown adipocyte differentiation, IM-
BATs were differentiated in the presence or absence of graded concentrations of DHT for
seven days. Increasing concentrations of DHT resulted in a dose-dependent reduction
in adipocyte differentiation and lipid accumulation (Figure 1B,C). To complement these
morphological studies, we investigated the effects of a range of DHT doses on gene expres-
sion during differentiation. Markers of adipogenesis were significantly downregulated
in a dose-dependent manner including Fabp4 (p < 0.05), C/EBPα (p < 0.05) and PPARG
(p < 0.05) (Figure 1D).
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Figure 1. Dihydrotestosterone (DHT) treatment reduces brown adipogenesis. (A) Representative images showing pres-
ence of the androgen receptor protein in brown preadipocytes and adipocytes. Blue—nuclear stain DAPI, green—andro-
gen receptor. (B) Representative differential interference contrast (DIC) microscopy images showing a reduction of lipid 
accumulation and brown adipocyte differentiation with increasing dose of DHT. (C) Representative images showing a 
reduction in lipid droplet formation with DHT, measured by Oil Red O in control and the 10 μM DHT. (D) Relative mRNA 
expression of adipogenic markers in brown adipocytes differentiated for seven days in the presence of different doses of 
DHT (t-test, * p < 0.05. Data shown is mean ( +/- SEM n = 4). 
2.3. Effects of DHT on Mitochondrial Respiratory Function in IMBATs 
To explore the effect of DHT on mitochondrial respiration, we measured oxygen con-
sumption rate (OCR) of IMBATs using a Seahorse XF analyzer. DHT treatment reduced 
the oxygen consumption rate (OCR) in IMBATs (Figure 2A). Basal mitochondrial respira-
tion was reduced by 64.2% (p < 0.01) when the cells had been incubated in medium with 
1μM DHT (Figure 2B). Maximal respiration was reduced by 9.68% (p < 0.05) and 26.9% (p 
< 0.01), respectively, when the cells were incubated in medium with 100 nM and 1 μM 
DHT. 
  
Figure 1. Dihydrotestosterone (DHT) treatment reduces brown adipogenesis. (A) Representative images showing presence
of the androgen receptor protein in brown preadipocytes and adipocytes. Blue—nuclear stain DAPI, green—androgen
receptor. (B) Representative differential interference contrast (DIC) microsco y i ages showing a reduction of lipid
accumulation and brown adipocyte dif erentiati r asing dose of DHT. (C) Represen ative images showing a
reduction in lipid droplet formation with DHT, measured by il ed in control and the 10 µM DHT. (D) Relative mRNA
expression of adipogenic markers in brown adipocytes differentiated for seven days in the presence of different doses of
DHT (t-test, * p < 0.05. Data shown is mean (±SEM n = 4).
2.3. Effects of DHT on Mi ochondrial Respirat ry Function in IMBATs
To explore the effect of DHT on mitochondrial respiration, we measured oxygen
consumption rate (OCR) of IMBATs using a Seahorse XF analyzer. DHT treatment reduced
the oxygen consumption rate (OCR) in IMBATs (Figure 2A). Basal mitochondrial respiration
was reduced by 64.2% (p < 0.01) when the cells had been incubated in medium with 1µM
DHT (Figure 2B). Maximal respiration was reduced by 9.68% (p < 0.05) and 26.9% (p < 0.01),
respectively, when the cells were incubated in medium with 100 nM and 1µM DHT.
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Figure 2. Reduced mitochondrial respiration in brown adipocytes treated with DHT. (A) Bioener-
getic profile of brown adipocytes treated with control (black line), 100 nM DHT (red line) and 1μM 
DHT (blue line). (B) Oxygen consumption rate (OCR) shows reduction in both basal and maximal 
respiration in brown adipocytes treated with either 100 nM DHT (red bar) and 1μM DHT (blue 
bar). One-way ANOVA with Holm–Sidak’s multiple comparison test, * p < 0.05, ** p < 0.01. Data 
shown are mean ( +/− ) SEM, n = 6. 
2.4. Effect of DHT on Brown Adipose Tissue Explants 
To further understand the effect of androgens on markers of brown adipose we 
treated mouse interscapular BAT explants with 100 nM DHT for 24 h. Androgen treatment 
had no significant effect on mitochondrial DNA (mtDNA) content (Figure 3A) or mito-
chondrial gene expression (Figure 3B). However, androgen treatment caused a significant 
reduction in several key metabolic markers of brown adipose tissue including UCP1, 
PCG1 and Cidea (Figure 3C). 
2.5. Effect of DHT on the Activation of the Thermogenic Gene Pathway 
Fully differentiated IMBATs were treated with the β-adrenergic agonist isopro-
terenol to simulate activation of the thermogenic pathway. Cells were cultured with and 
without 100 nM DHT and expression levels of UCP1 mRNA were measured by qPCR. As 
expected, isoproterenol stimulated UCP1 expression. Androgen treatment significantly 
reduced the increase in UCP1 expression to almost baseline levels (Figure 3D). 
  
Figure 2. Reduced mitochondrial respiration in brown adipocytes treated with DHT. (A) Bioenergetic
profile of brown adipocytes treated with control (black line), 100 nM DHT (red line) and 1µM
DHT (blue line). (B) Oxygen consumption rate (OCR) shows reduction in both basal and maximal
respiration in brown adipocytes treated with either 100 nM DHT (red bar) and 1µM DHT (blue bar).
One-way ANOVA with Holm–Sidak’s multiple comparison test, * p < 0.05, ** p < 0.01. Data shown
are mean (±) SEM, n = 6.
2.4. Effect of DHT on Brown Adipose Tissue Explants
To further understand the effect of androgens on markers of brown adipose we treated
mouse interscapular BAT explants with 100 nM DHT for 24 h. Androgen treatment had no
significant effect on mitochondrial DNA (mtDNA) content (Figure 3A) or mitochondrial
gene expression (Figure 3B). However, androgen treatment caused a significant reduction
in several key metabolic markers of brown adipose tissue including UCP1, PCG1 and
Cidea (Figure 3C).
2.5. f ect of T on the ctivation of the Ther ogenic Gene Pathway
Ful y differentiated IMBATs were t a ed with the β-adrenergic agonist isoproterenol
to simulate activ ion of the thermogenic pathway. Cells were cultured with an it out
100 nM DHT and expression lev l f UCP1 mRNA were measured by qPCR. As expected,
iso ro renol stimulated UCP1 expression. Androgen treatment significantly reduced the
increase in UCP1 expression to almo t baseline levels (Figure 3D).




Figure 3. DHT treatment reduces UCP1 gene expression and activation of the thermogenic path-
way. (A) Relative mitochondrial DNA content in brown adipose tissue treated with either control 
or 100 nM DHT. Representative images showing no change in mitochondrial number, observed by 
MitoTracker Red in control and the DHT treated brown adipocytes. (B) Relative mRNA expres-
sion of mitochondrial function genes in brown adipose tissue treated with either control or 100 nM 
DHT. (C) Relative mRNA expression of brown adipose markers in brown adipose tissue treated 
with either control or 100 nM DHT. (D) Thermogenic activation measured by UCP1 mRNA in-
crease in brown adipocytes treated with either control, 1μM isoproterenol, or 1 μM isoproterenol 
co-treated with 100 nM of DHT. t-test, * p < 0.05. Data shown is mean ( +/− ) SEM n = 4). 
2.6. BAT is an Active Endocrine Organ and Secretes an Array of Adipokines 
To gain a better understanding of the adipokines secreted by intact BAT we used 
proteome profiler adipokine arrays to profile the relative amounts of 38 adipokines se-
creted from BAT explants over 24 h. Interestingly, BAT secreted high levels of several 
adipokines such as adiponectin and resistin that have been shown to be altered in women 
with PCOS or by high levels of androgen [20,21,29,30] (Figure 4A). 
2.7. Explants of Brown Adipose Tissue Have Distinct Adipokine Gene Expression Profiles 
Compared to White Adipose Tissue 
Using qPCR data, we compared the gene expression levels of adipokines in mouse 
WAT and BAT explants. Four adipokines were expressed at lower levels in BAT than in 
WAT. Approximately 15 adipokines shared similar levels of expression in BAT compared 
to WAT. However, 11 adipokines were expressed at higher levels in BAT than WAT ( 
Figure 4B). 
  
Figure 3. treat ent reduces UCP1 gene expres ion and activation of the thermogenic pathway.
(A) Relative mitochondrial DNA content in brown adipose tissue treated with either control or
100 nM DHT. Representative images showing no change in mitochondrial number, observed by
MitoTracker Red in control and the DHT treated brown adipocytes. (B) Relative mRNA expression
of mitochondrial function genes in brown adipose tissue treated with either control or 100 nM DHT.
(C) Relative mRNA expression of brown adipose markers in brown adipose tissue treated with either
control or 100 nM DHT. (D) Thermogenic activation measured by UCP1 mRNA increase in brown
adipocytes treated with either control, 1µM isoproterenol, or 1 µM isoproterenol co-treated with
100 nM of DHT. t-test, * p < 0.05. Data shown is mean (±) SEM n = 4).
2.6. BAT Is an Active Endocrine Organ and Secretes an Array of Adipokines
To gain a better understanding of the adipokines secreted by intact BAT we used
proteome profiler adipokine arrays to profile the relative amounts of 38 adipokines secreted
from BAT explants over 24 h. Interestingly, BAT secreted high levels of several adipokines
such as adiponectin and resistin that have been shown to be altered in women with PCOS
or by high levels of androgen [20,21,29,30] (Figure 4A).
2.7. Explants of Brown Adipose Tissue Have Distinct Adipokine Gene Expression Profiles
o pared to hite Adipose Tis ue
sing qPCR data, we compared the g ne expression leve s of adipokines in mouse WAT
and BAT explants. Four adipokines wer exp ssed at lower evels in BAT than in WAT.
Approximately 15 adipokines shared similar levels of xpression in BAT compared to WAT.
However, 11 adipokines were express d at higher levels in BAT than WAT (Figure 4B).
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Figure 4. (A) Heat-map produced from proteome profiler adipokine arrays used to profile the levels of secreted adipokines 
from interscapular BAT explants cultured in control medium for 24 h. Red indicates adipokines secreted at high levels 
Figure 4. (A) Heat-map produced from proteome profiler adipokine arrays used to profile the levels of secreted adipokines
from interscapular BAT explants cultured in control medium for 24 h. Red indicates adipokines secreted at high levels and
green indicates adipokines secreted at lower levels from brown adipose tissue (n = 4). (B) Heat-map showing adipokine
gene expression in BAT relative to WAT. On the scale bar, red indicates genes expressed at lower levels in BAT and green
indicates genes expressed at higher levels in BAT, black represents genes that are expressed equally in BAT and WAT.
(C) Relative mRNA expression of adipokine screen in IMWATs and IMBATs treated with either control of 10 µM DHT. t-test,
* p < 0.05, ** p < 0.01, *** p < 0.005. Data shown are mean (±) SEM, n = 6–8.
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2.8. Effect of DHT on Adipokine Gene Expression in Differentiated IMWATs and IMBATs
To further characterize the response of brown adipocytes to androgen we looked at
the effects on adipokine gene expression after treating fully differentiated IMBATs with
DHT and examined changes in gene expression by qPCR for a panel of 25 adipokines.
We compared the panel of expressed genes with that obtained after similar treatment of
IMWATs. DHT treatment significantly altered the expression of several adipokines genes in
IMBATs (Figure 4C). Of particular interest is expression of adiponectin that was significantly
decreased by DHT (p < 0.01). Plasminogen activator inhibitor-1 (PAI-1) showed an increase
(p < 0.001), C3, an immune marker was significantly decreased (p < 0.01) and resistin,
an adipokine involved in obesity and Type-2 diabetes, was also significantly decreased
(p < 0.05). In IMWATs there was a similar decrease in adiponectin expression (p < 0.01)
and an increase in PAI-1 expression (p < 0.05). However, DPP-4 was downregulated in
IMWATs (p < 0.05) but upregulated in IMBATs (p < 0.05). Visfatin was the only adipokine
to be modulated solely in IMWATs and was significant upregulated (p < 0.05). Interestingly
the magnitude of response to androgen treatment tended to be greater in IMBATs than in
IMWATs (Figure 4C).
3. Discussions
In this study, we investigated the role of the nonaromatizable androgen DHT in a well
characterized, immortalized mouse brown adipocyte cell line and in explants of mouse
brown adipose tissue. The importance of adipose tissue in the pathophysiology of PCOS
is well established but studies to date have mainly focused on the relevance of white adi-
pose depots and the possible role of androgens in WAT dysfunction [17,31,32]. Interest in
brown adipose tissues has been growing following the discovery of significant depots of
metabolically active brown adipose tissue in healthy adult humans [7,33]. Brown adipose
tissue was first described in small mammals and infants as an adaptation to defend against
the cold [6,34]. The abundance of BAT lessens with increasing age and was thought to be
completely lost by adulthood. BAT is the major site of adaptive non-shivering thermogen-
esis, both during cold exposure and after meals in so called postprandial thermogenesis.
The inverse relationship between the BAT activity and body fatness suggests that BAT,
through increasing energy expenditure, is protective against body fat accumulation [8,35].
This has led to BAT being viewed as a promising therapeutic target for combating human
obesity and related metabolic disorders [36,37]. Studies in both rodents and humans have
shown that BAT is activated on food intake [38–40]. Furthermore, postprandial thermo-
genesis is higher in individuals with higher BAT activities and it has been reported that
polymorphisms in the UCP1 gene can negatively affect PPT after a high-fat meal [37,41].
Robinson and colleagues showed that while resting energy expenditure was similar in
women with and without PCOS, postprandial thermogenesis was reduced in both obese
and lean women with PCOS [42]. This decreased postprandial thermogenesis may predis-
pose women with PCOS to weight gain and help to explain the increased prevalence of
obesity in women with PCOS.
Our findings provide further evidence of androgens modulating mitochondrial respi-
ration in adipose tissue and may help elucidate the molecular mechanisms underpinning
disordered energy balance in women with PCOS. We show that brown preadipocytes and
adipocytes contain androgen receptor and that brown adipogenesis is inhibited in a dose-
dependent manner by androgen treatment. This can be clearly visualized through both
a reduction in lipid droplets and key adipogenic markers. Androgen signaling may also
play a direct role in the normal physiology of brown adipose tissue. We show that IMBATs
cultured in the presence of DHT have significantly reduced mitochondrial respiration.
These mitochondrial defects are likely to contribute to reduced energy expenditure and
non-shivering thermogenesis.
Furthermore, DHT treatment appeared to have a “whitening” effect on interscapular
BAT explants treated with androgens, as seen by a reduction of key markers of BAT
including UCP1, PGC1 and Cidea. Although UCP1 is a major driving force in non-shivering
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thermogenesis, a number of other factors including mitochondrial density and biogenesis
are required for effective thermogenesis and energy expenditure [43]. Our results show that
expression of PGC-1α, a critical regulator of mitochondrial biogenesis was downregulated
by androgen. While there was no effect of androgen exposure on either mitochondrial
gene expression or mitochondrial DNA content, the observed reduction in mitochondrial
respiration shows that mitochondrial function is significantly impaired by androgen.
From a clinical viewpoint, decreased mitochondrial respiratory activity is also im-
plicated in the development of type-2 diabetes and is thought to be modulated, in part,
by insulin resistance [44–46]. Insulin resistance plays a central role in the pathogenesis
of both PCOS and type-2 diabetes and has a bearing on therapeutic strategy. Metformin
has been widely used in management of PCOS and there are a growing number of clinical
trials that suggest therapeutic benefits of novel inositol treatments [47,48]. There is also evi-
dence that metformin treatment increases mitochondrial respiration, membrane potential,
and ATP levels in hepatocytes [49].
Under normal physiological conditions, thermoregulation in mammals is coordinated
and governed by the hypothalamus via the activation of the sympathetic nervous sys-
tem. We wanted to investigate the effect of excess androgens on the activation of the
thermogenic pathway. To this end, we exposed IMBATs to the β-adrenergic agonist, isopro-
terenol, in order to activate the thermogenic pathway and measured expression levels of
UCP1, a well-accepted marker of thermogenesis activation [50,51]. We found that brown
adipocytes pretreated with androgens showed reduced levels of UCP1 and hence reduced
activation of the thermogenic pathway. This could provide one possible mechanism to
understand reduced postprandial thermogenesis found in women with PCOS. In a similar
fashion Barbato et al., recently showed that glutathione decrement drives the thermogenic
program in adipose cells. However, adipocytes co-treated with isoproterenol and a glu-
tathione ester showed blunted activation of the thermogenic program [51]. These results
provide insight into the molecular mechanism that might underlie similar findings in a
recently published study of a prenatally androgenized sheep model of PCOS. This study
showed postprandial thermogenesis is also suppressed by androgens and was associated
with a reduction of UCP1 in interscapular brown adipose tissue [25].
Finally, we characterized adipokine profiles in brown adipose tissue. Studies of animal
models of PCOS suggest that exposure to excess androgen during or well before puberty
increases adiposity and influences circulating levels of adipokines [52]. Several studies have
suggested a role for adipokines as a link between the typical metabolic and reproductive
abnormalities found in PCOS [13,20,53,54]. Our results also show that BAT, like WAT, is an
active endocrine organ and secretes a range of adipokines, Adiponectin, resistin and PAI-1
are all secreted at high levels from BAT and production of these key adipokines is commonly
disordered in PCOS. It is important to note that although BAT is an active endocrine organ
and secretes a range of adipokines, BAT and WAT show distinctly different adipokine
gene expression profiles. Furthermore, in a screen of adipokine abundance in androgen
treated IMBATS, we observed a significant reduction in adiponectin (an “anti-obesity”
adipokine) and resistin expression while PAI-1 was significantly increased. A similar effect
was observed in IMWATs treated with androgen. Adiponectin expression was reduced and
PAI-1 expression increased by DHT. The reduction of adiponectin is consistent with data
showing that women with PCOS and androgenized mice have lower serum adiponectin
levels than in controls and reduced adiponectin gene expression in subcutaneous and
omental adipose depots has been demonstrated in women with PCOS [20,52,55,56]. We also
show that there was a greater response in adipokine production to androgen treatment
in brown adipocytes when compared to white adipocytes. While both IMWATs and
IMBATs show a reduction in adiponectin after DHT treatment, IMBATs but not IMWATs
also have reduced production of resistin, desnutrin/ATGL and RBP-4. Reduced levels
of desnutrin/ATGL, the rate limiting lipase enzyme may impair the release of free fatty
acids required for oxidation and activation of UCP1. The lower levels of BAT-associated
genes support the notion of a “whitening” of brown adipocytes in response to androgen
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treatment. DPP-4, while downregulated in IMWATs is upregulated in IMBATs and would
likely impact on insulin responses due to action on GLP-1 and incretin.
Although these studies focus on the nonaromatizable androgen DHT it is important
to remember that aromatase activity may play a role in androgen and estrogen interactions
with BAT in-vivo. In particular, estrogen is known to increase expression of UCP genes in
rodent adipose tissue [57] and regulate thermogenesis in BAT via hypothalamic AMPK [58].
In conclusion, our study illustrates a novel role for androgen signaling in inhibiting
mitochondrial respiration, brown adipogenesis and in “whitening” of brown adipose tissue.
Androgen treatment attenuates the β-adrenoceptor-stimulated increase in UCP1 in IM-
BATs and provides a molecular explanation for the link between hyperandrogenemia and
reduced thermogenic capacity. Together, these findings provide insight into the molecular
mechanisms that underlie normal regulation of BAT but, in particular, highlight a potential
role for androgen action on BAT function that may contribute to the pathophysiology of
PCOS and associated disorders of energy balance.
4. Materials and Methods
4.1. IMBAT and IMWAT Preadipocyte Culture and Adipocyte Differentiation
Immortalized mouse brown (IMBATs) preadipocytes were cultured at 33 ◦C with
10% CO2 in DMEM/F12 1:1 (Invitrogen, Life Technologies, Paisley, Scotland), supple-
mented with 4.5 g/L glucose, 10% FBS (Sigma-Aldrich Co.; St. Louis, MO, USA), and 1%
penicillin/streptomycin (BioWhittaker, Vervier, Belgium) as described previously [59].
IMBATs were differentiated in DMEM/F12 1:1 with 4.5 g/L glucose, 10% FBS, 1% peni-
cillin/streptomycin supplemented with 170 nM insulin; 250 nM dexamethasone; 500 µM
isobutylmethylxanthine; 125 nM indomethacin (Sigma) and 1 nM T3 (Sigma) at 37 ◦C
with 5% CO2. After 48 h, the medium was replaced with fresh DMEM/F12 1:1, 4.5 g/L
glucose, 10% FBS, 1% penicillin/streptomycin supplemented with 170 nM insulin and
1 nM triiodothyronine (T3) and cultured for a further 12 days until fully differentiated.
IMWATs were differentiated in DMEM/F12 1:1 with 4.5 g/L glucose, 10% FBS, 1% peni-
cillin/streptomycin supplemented with 170 nM insulin (Sigma); 250 nM dexamethasone
(Sigma); 500 µM isobutylmethylxanthine (Sigma); 2.5 µM rosiglitazone (VWR, VWR Com-
pany, Darmstadt, Germany) at 37 ◦C with 5% CO2. After 48 h, the medium was replaced
with DMEM/F12 1:1, 4.5 g/L glucose, 10% FBS, 1% penicillin/streptomycin supplemented
with 170 nM insulin and cultured for a further 12 days until fully differentiated. Medium
was changed every 2–3 days.
4.2. Immunohistochemistry
IMBAT preadipocytes and adipocytes were washed twice in PBS and then fixed in 4%
paraformaldehyde for 15 min at 37 ◦C. Cells were permeabilized using ice-cold acetone at
−20 ◦C for 5 min and then washed three times with PBS. Non-specific binding was blocked
using 20% normal goat serum incubation for 1 h at room temperature. Cells were incubated
overnight at 4 ◦C with a rabbit anti-androgen-receptor primary antibody at 1:300 dilution
(Abcam, Cambridge, MA, USA), this concentration has been previously shown to work
effectively in-house for mouse ovary immunohistochemistry. After several washes with
PBS, the cells were incubated with an Alexa Fluro 488-conjugated secondary antibody
for 1 h at room temperature. Cells were counterstained and preserved using Prolong
Gold medium containing 4′6-diamidino-2-phenylindole (DAPI; Invitrogen) and examined
under a fluorescent microscope (Nikon Eclipse TE300). Distribution of mitochondria was
examined by live cell imaging using MitoTracker Red as per manufacturer’s instructions
(Invitrogen, Carlsbad, CA, USA).
4.3. Effect of DHT on IMBAT Differentiation
To investigate the effect of androgens on brown adipocyte differentiation, IMBATs
were differentiated using the protocol described above but this time in the presence of
different doses of DHT (10 nM, 100 nM, 1 µM and 10 µM) or vehicle control (ethanol) for
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7 days. Differential interference contrast (DIC) microscopy was used to judge the effect of
different doses of DHT on IMBAT differentiation and lipid accumulation (Nikon Eclipse
TE300, Nikon, Tokyo, Japan). Cells were collected to determine the effects of DHT on
adipogenic markers. Cells were collected in QIAzol (QIAgen, Qiagen, Hilden, Germany)
and stored at −80 ◦C until needed for gene expression studies.
4.4. Effect of DHT on IMBAT Oxygen Consumption Rate (OCR)
IMBATs were seeded at 2 × 104 cells/well in XFe24 microplate coated with 0.2%
gelatin, the cells were differentiated as described above and treated with androgen for
48 h. The cells were washed twice, and medium was replaced with XF Assay medium
containing 4.5 g/L glucose, 4.0 mM Glutamine and 1.0 mM Sodium pyruvate (pH adjusted
to 7.35 ± 0.05 using 1 mol/L NaOH). The plates were placed in a 37 ◦C incubator with-
out CO2 for one hour prior to the assay. OCR measurements were performed using the
Seahorse Biosciences XFe Analyzer. All experiments were performed at 37 ◦C. After mea-
surement of basal respiration, oligomycin (2.0 µM), FCCP (1.0 µM), rotenone/antimycin A
(1.0 µM/1.0 µM) were added sequentially to measure ATP production, maximal respiratory,
and non-mitochondrial respiration (NMR), respectively.
4.5. Brown Adipose Tissue Explants and DHT Treatment
C57BL/6 female mice were culled and the interscapular brown adipose tissue and in-
guinal white adipose tissue collected and processed immediately for quantitative, real time
PCR (qPCR). For culture experiments, fresh brown adipose tissue was cut into 5–10 mg
pieces and cultured in 12-well plates in 1 mL serum-free DMEM/F12, 1:1 supplemented
with 1% penicillin/streptomycin at 37 ◦C with 5% CO2. BAT explants were treated with
either 100 nM DHT or vehicle control (ethanol) for 24 h and collected for subsequent gene
expression analysis by QPCR. Cultured medium was collected for adipokine array analysis.
All animal studies were carried out according to UK Home Office guidelines. To investigate
the effect of androgens on the activation of the thermogenic pathway, IMBATs were fully
differentiated and were serum starved in DMEM/F12 1:1 with 4.5 g/L glucose, 1% peni-
cillin/streptomycin and no FBS for 24 h. Cells were then treated with either 100 nM DHT or
vehicle control (ethanol) for 24 h. After 19 h, all cells were treated with 1 µM isoproterenol
(VWR) for 5 h. Cells were collected in QIAzol (QIAgen, Qiagen, Hilden, Germany) and
UCP1 gene expression levels were measured.
4.6. RNA Extraction and Quantitative Real Time PCR
Samples were homogenised in QIAzol using a QIAShredder column (QIAgen, Qiagen,
Hilden, Germany). Total RNA extraction used a method combining both QIAzol and
QIAgen Mini RNA kits [60]. Purity and quantity of RNA was measured using a Nan-
odrop 1000 (NanoDrop Technologies, Wilmington, DE, USA). 1 µg of RNA was reversed
transcribed using random hexamers and Superscript III according to manufacturer’s in-
structions (Invitrogen). QPCR was carried out in 384 well plates using POWER SYBR Green
(Applied Biosystems, Foster City, CA, USA), according to the manufacturer’s instructions,
on an Applied Biosystems 7900 HT instrument. Primers were designed with Primer3 [61]
(available on request). Relative expression levels were determined using the delta delta Ct
method [62]. Control samples were normalized to 1 and actin B was used as an internal
reference gene and has previously been shown to be an appropriate and stable reference
gene for adipose tissue [63–65]. All samples were analysed in triplicate and dissociation
curves were used to ensure that a single product was formed. For mitochondrial DNA
quantification, the ratio of mtDNA (ND2) to nuclear DNA (LPL) in adipocytes, which re-
flects the cellular mitochondrial number, was determined by qPCR. DNA was isolated
from adipocytes according to the manufacturer’s protocol (Qiagen, Valencia, CA, USA).
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4.7. Expression of Adipokine Genes in IMWATs and IMBATs after DHT Treatment
To investigate the response of adipokine genes to excess androgen treatment we fully
differentiated IMWATs and IMBATs for 12 days. The cells were then serum starved in
DMEM/F12 1:1 with 4.5 g/L glucose, 1% penicillin/streptomycin and no FBS for 24 h.
Cells were then treated with either 10 µM DHT (Sigma) or vehicle control (ethanol) for
24 h. Cells were collected in QIAzol (QIAgen, Qiagen, Hilden, Germany) and stored at
−80 ◦C until needed for adipokine gene expression analysis. A panel of 25 adipokines
were selected based on their relevance to PCOS, especially those based on obesity and
insulin resistance.
4.8. Secreted Adipokine Array
To further characterize brown adipose tissue in mice, we used the Proteome Profiler
Mouse Adipokine Array Kit (R & D, Minneapolis, MN, USA) to measure the levels of
secreted adipokines in BAT cultured media, using the manufacturer’s instructions. Pro-
teome Profiler membranes were visualized using a ImageQuant LAS 4000 (Amersham,
The Netherlands).
4.9. Statistical Analysis
Statistical analysis of qPCR data was carried out according to Schmittgen [62] using
a two-tailed, unpaired Student t-test. A p-value of <0.05 was considered statistically
significant. Adjustment for multiple comparisons was made using the Benjamini–Hochberg
method [66]. Data are presented graphically as mean (±SEM). Analysis was carried out
using Prism 6.0 (GraphPad Software Inc., San Diego, CA, USA).
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